Subscribe to our Newsletters !!
A lion or eagle may come to mind when considering
In science, the interference of materials, reagent
Dr. Mohammed Enayat’s recent testimony on his ag
This year, the Hamburg based life sciences company
Unlike other medications, Vyvanse (Lisdexamfetamin
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
26th December, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending Sep 2022 according to IQVIA.
Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.
